Empowering Perinatal Adolescents Through Writing (NCT06771817) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Empowering Perinatal Adolescents Through Writing
United States30 participantsStarted 2025-03-26
Plain-language summary
This is a feasibility and acceptability study of Written Exposure Therapy (WET) for PTSD in pregnant and postpartum adolescents and youth with PTSD.
Who can participate
Age range15 Years – 24 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Stated willingness to comply with all study procedures and availability for the duration of the study
✓. Have been referred by a clinician to the study or receiving standard of care treatment for pregnancy or post-partum follow-up
✓. Aged 15-24 at time of screening
✓. Either have Gestational age \>12 weeks or be \<1 year postpartum at time of screening
✓. Able and willing to provide informed consent if 18 years of age or above or the legal guardian must be able and willing to provide informed consent if participant is less than 18 years of age and participant willing and able to provide assent if less than 18 years of age
✓. Able to read, write and speak in English and Spanish; if the participant is under age 18, parents must be able to understand spoken or written English or Spanish.
✓. Have the ability to complete clinical evaluations and self-report measures.
✓. Meet diagnostic or subthreshold criteria for PTSD.
Exclusion criteria
✕. Have any condition for which, in the opinion of the investigator or designee, study participation would not be in their best interest (including but not limited to cognitive impairment, unstable general medical condition, intoxication, active psychosis) or that could prevent, limit, or confound the protocol-specified assessments.
✕. Have current mania, hypomania, or psychosis
✕
What they're measuring
1
Feasibility of Written Exposure Therapy
Timeframe: From enrollment to study exit visit at week 12
Trial details
NCT IDNCT06771817
SponsorUniversity of Texas Southwestern Medical Center